<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Bioretec Ltd. — News on 6ix</title>
<link>https://6ix.com/company/bioretec-ltd</link>
<description>Latest news and press releases for Bioretec Ltd. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 12:03:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/bioretec-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d5225ebeedb30cb6f67f41.webp</url>
<title>Bioretec Ltd.</title>
<link>https://6ix.com/company/bioretec-ltd</link>
</image>
<item>
<title>New shares of Bioretec Ltd registered with the trade register</title>
<link>https://6ix.com/company/bioretec-ltd/news/new-shares-of-bioretec-ltd-registered-with-the-trade-register</link>
<guid isPermaLink="true">https://6ix.com/company/bioretec-ltd/news/new-shares-of-bioretec-ltd-registered-with-the-trade-register</guid>
<pubDate>Tue, 28 Apr 2026 12:03:00 GMT</pubDate>
<description>As previously announced, Bioretec Ltd ("Bioretec" or the "Company") has completed its rights issue (the "Offering"). Bioretec announced the final results of the Offering on 24 April 2026.</description>
</item>
<item>
<title>Final results of Bioretec Ltd's rights issue</title>
<link>https://6ix.com/company/bioretec-ltd/news/final-results-of-bioretec-ltds-rights-issue-1</link>
<guid isPermaLink="true">https://6ix.com/company/bioretec-ltd/news/final-results-of-bioretec-ltds-rights-issue-1</guid>
<pubDate>Fri, 24 Apr 2026 16:18:00 GMT</pubDate>
<description>Bioretec Ltd Company announcement 24 April 2026 at 6:45 p.m. EEST</description>
</item>
<item>
<title>Inside information: Preliminary result of Bioretec Ltd's rights issue</title>
<link>https://6ix.com/company/bioretec-ltd/news/inside-information-preliminary-result-of-bioretec-ltds-rights-issue-1</link>
<guid isPermaLink="true">https://6ix.com/company/bioretec-ltd/news/inside-information-preliminary-result-of-bioretec-ltds-rights-issue-1</guid>
<pubDate>Thu, 23 Apr 2026 13:51:00 GMT</pubDate>
<description>Bioretec Ltd ("Bioretec" or the "Company") announced on 27 March 2026 that the Board of Directors of Bioretec has decided to offer Bioretec's shareholders up to 1,477,828,416 new shares (the "New Shares") for subscription primarily on the basis of shareholders' pre-emptive subscription right in the same proportion as they already hold shares in the Company and secondarily by other shareholders or by other persons (the "Offering"). The subscription period for the Offering ended on 21 April 2026 a</description>
</item>
<item>
<title>NOTICE OF THE ANNUAL GENERAL MEETING OF BIORETEC LTD</title>
<link>https://6ix.com/company/bioretec-ltd/news/notice-of-the-annual-general-meeting-of-bioretec-ltd</link>
<guid isPermaLink="true">https://6ix.com/company/bioretec-ltd/news/notice-of-the-annual-general-meeting-of-bioretec-ltd</guid>
<pubDate>Mon, 20 Apr 2026 15:41:00 GMT</pubDate>
<description>The shareholders of Bioretec Ltd are hereby invited to the Annual General Meeting to be held on 8 May 2026 at 11:00 a.m. (Finnish time) at Bioretec premises in the auditorium of Tampark, at the address Yrittäjänkulma 5, FI-33710 Tampere, Finland. The reception of persons who have registered for the meeting and the distribution of voting tickets will commence at 10:30 a.m. (Finnish time) at the meeting venue.</description>
</item>
<item>
<title>Bioretec Ltd publishes an exemption document relating to its rights issue</title>
<link>https://6ix.com/company/bioretec-ltd/news/bioretec-ltd-publishes-an-exemption-document-relating-to-its-rights-issue-1</link>
<guid isPermaLink="true">https://6ix.com/company/bioretec-ltd/news/bioretec-ltd-publishes-an-exemption-document-relating-to-its-rights-issue-1</guid>
<pubDate>Thu, 02 Apr 2026 13:50:00 GMT</pubDate>
<description>Bioretec Ltd ("Bioretec" or the "Company") announced on 27 March 2026 that it is commencing a rights issue, in which Bioretec offers up to 1,477,828,416 new shares (the "New Shares") for subscription by Bioretec's existing shareholders in accordance with the pre-emptive right of shareholders with a subscription price of EUR 0.01 per New Share (the "Offering").</description>
</item>
<item>
<title>Inside information: Bioretec Ltd's Board of Directors resolved on a rights issue of up to approximately EUR 14.8 million and publishes the terms and conditions of the rights issue</title>
<link>https://6ix.com/company/bioretec-ltd/news/inside-information-bioretec-ltds-board-of-directors-resolved-on-a-rights-issue-of-up-to-approximately-eur-148-million-and-publishes-the-terms-and-conditions-of-the-rights-issue</link>
<guid isPermaLink="true">https://6ix.com/company/bioretec-ltd/news/inside-information-bioretec-ltds-board-of-directors-resolved-on-a-rights-issue-of-up-to-approximately-eur-148-million-and-publishes-the-terms-and-conditions-of-the-rights-issue</guid>
<pubDate>Fri, 27 Mar 2026 12:50:00 GMT</pubDate>
<description>The Board of Directors of Bioretec Ltd ("Bioretec" or the "Company") has today 27 March 2026, based on the authorisation of the Extraordinary General Meeting of the Company held on 27 March 2026, resolved to offer Bioretec's shareholders up to 1,477,828,416 new shares (the "New Shares") for subscription primarily on the basis of shareholders' pre-emptive subscription right in the same proportion as they already hold shares in the Company (the "Existing Shares") and secondarily by other sharehold</description>
</item>
<item>
<title>The Finnish Financial Supervisory Authority has granted Stephen Industries Inc Oy and Kustaa Poutiainen a permanent exemption from the obligation to launch a mandatory public takeover bid</title>
<link>https://6ix.com/company/bioretec-ltd/news/the-finnish-financial-supervisory-authority-has-granted-stephen-industries-inc-oy-and-kustaa-poutiainen-a-permanent-exemption-from-the-obligation-to-launch-a-mandatory-public-takeover-bid-1</link>
<guid isPermaLink="true">https://6ix.com/company/bioretec-ltd/news/the-finnish-financial-supervisory-authority-has-granted-stephen-industries-inc-oy-and-kustaa-poutiainen-a-permanent-exemption-from-the-obligation-to-launch-a-mandatory-public-takeover-bid-1</guid>
<pubDate>Thu, 26 Mar 2026 17:46:00 GMT</pubDate>
<description>Bioretec Ltd ("Bioretec" or the "Company") has announced on 10 March 2026 that it is planning a rights issue based on the shareholders' pre-emptive subscription right (the "Offering").</description>
</item>
<item>
<title>Change to the publication date of Business Review: Bioretec publishes January-March 2026 Business Review on 15 May 2026</title>
<link>https://6ix.com/company/bioretec-ltd/news/change-to-the-publication-date-of-business-review-bioretec-publishes-january-march-2026-business-review-on-15-may-2026</link>
<guid isPermaLink="true">https://6ix.com/company/bioretec-ltd/news/change-to-the-publication-date-of-business-review-bioretec-publishes-january-march-2026-business-review-on-15-may-2026</guid>
<pubDate>Tue, 24 Mar 2026 12:19:00 GMT</pubDate>
<description>Bioretec Ltd publishes its January-March 2026 Business Review on 15 May 2026. The earlier announced publication date was 14 May 2026.</description>
</item>
<item>
<title>Bioretec Ltd's Financial Statements and Annual Report 2025 published</title>
<link>https://6ix.com/company/bioretec-ltd/news/bioretec-ltds-financial-statements-and-annual-report-2025-published</link>
<guid isPermaLink="true">https://6ix.com/company/bioretec-ltd/news/bioretec-ltds-financial-statements-and-annual-report-2025-published</guid>
<pubDate>Fri, 13 Mar 2026 16:07:00 GMT</pubDate>
<description>Bioretec Ltd has today published its 2025 Financial Statements and Annual Report. The publications are attached to this release and also available in Finnish and English on the company's website at investors.bioretec.com/en/reports_and_presentations.</description>
</item>
<item>
<title>Inside information: Timo Lehtonen takes on a new role at Bioretec as External Executive Advisor and steps down from the management team</title>
<link>https://6ix.com/company/bioretec-ltd/news/inside-information-timo-lehtonen-takes-on-a-new-role-at-bioretec-as-external-executive-advisor-and-steps-down-from-the-management-team</link>
<guid isPermaLink="true">https://6ix.com/company/bioretec-ltd/news/inside-information-timo-lehtonen-takes-on-a-new-role-at-bioretec-as-external-executive-advisor-and-steps-down-from-the-management-team</guid>
<pubDate>Thu, 12 Mar 2026 16:10:00 GMT</pubDate>
<description>Timo Lehtonen, the current Chief Technology Officer of Bioretec Ltd ("Bioretec" or the "Company"), will transition to the role of External Executive Advisor (Technology & Strategy) and step down from the Company's management team and Chief Technology Officer role as of 6 July 2026.</description>
</item>
<item>
<title>Notice of the Extraordinary General Meeting of Bioretec Ltd</title>
<link>https://6ix.com/company/bioretec-ltd/news/notice-of-the-extraordinary-general-meeting-of-bioretec-ltd</link>
<guid isPermaLink="true">https://6ix.com/company/bioretec-ltd/news/notice-of-the-extraordinary-general-meeting-of-bioretec-ltd</guid>
<pubDate>Tue, 10 Mar 2026 20:15:00 GMT</pubDate>
<description>NOTICE OF THE EXTRAORDINARY GENERAL MEETING OF BIORETEC LTD</description>
</item>
<item>
<title>Inside information: Bioretec Ltd's Board of Directors is assessing a potential rights issue in the near future</title>
<link>https://6ix.com/company/bioretec-ltd/news/inside-information-bioretec-ltds-board-of-directors-is-assessing-a-potential-rights-issue-in-the-near-future-1</link>
<guid isPermaLink="true">https://6ix.com/company/bioretec-ltd/news/inside-information-bioretec-ltds-board-of-directors-is-assessing-a-potential-rights-issue-in-the-near-future-1</guid>
<pubDate>Fri, 13 Feb 2026 08:22:00 GMT</pubDate>
<description>The Board of Directors of Bioretec Ltd ("Bioretec" or the "Company") is assessing a potential rights issue based on the shareholders' pre-emptive subscription right (the "Offering") in the near future. The targeted gross proceeds to be raised through the Offering would preliminarily be approximately EUR 15 million.</description>
</item>
<item>
<title>Bioretec Ltd's financial statements bulletin for January-December 2025 will be published on February 13, 2026</title>
<link>https://6ix.com/company/bioretec-ltd/news/bioretec-ltds-financial-statements-bulletin-for-january-december-2025-will-be-published-on-february-13-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/bioretec-ltd/news/bioretec-ltds-financial-statements-bulletin-for-january-december-2025-will-be-published-on-february-13-2026-1</guid>
<pubDate>Mon, 09 Feb 2026 16:09:00 GMT</pubDate>
<description>Bioretec Ltd will publish its financial statements bulletin for the financial year 1 January-31 December 2025 on Friday, 13 February 2026 at approximately 9:30 a.m. EET.</description>
</item>
<item>
<title>Proposals of the Shareholders' Nomination Board of Bioretec Ltd to the Annual General Meeting 2026</title>
<link>https://6ix.com/company/bioretec-ltd/news/proposals-of-the-shareholders-nomination-board-of-bioretec-ltd-to-the-annual-general-meeting-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/bioretec-ltd/news/proposals-of-the-shareholders-nomination-board-of-bioretec-ltd-to-the-annual-general-meeting-2026-1</guid>
<pubDate>Fri, 30 Jan 2026 12:14:00 GMT</pubDate>
<description>The Shareholders' Nomination Board of Bioretec Ltd ("Bioretec") has resolved to make the following proposals to the Annual General Meeting. The Annual General Meeting of Bioretec is scheduled to be held on 8 May, 2026, and the company will publish the notice of the meeting separately.</description>
</item>
<item>
<title>CMS Transitional Pass-Through Payment (TPT) description for HCPCS code C1741 has been revised</title>
<link>https://6ix.com/company/bioretec-ltd/news/cms-transitional-pass-through-payment-tpt-description-for-hcpcs-code-c1741-has-been-revised-1</link>
<guid isPermaLink="true">https://6ix.com/company/bioretec-ltd/news/cms-transitional-pass-through-payment-tpt-description-for-hcpcs-code-c1741-has-been-revised-1</guid>
<pubDate>Fri, 16 Jan 2026 17:03:00 GMT</pubDate>
<description>Bioretec Ltd, a pioneer in absorbable orthopedic implants, was granted Transitional Pass-Through Payment (TPT) status by the U.S. Centers for Medicare & Medicaid Services (CMS) for its RemeOs™ Trauma Screw, effective October 1, 2025.</description>
</item>
<item>
<title>Tuukka Paavola appointed as Chief Financial Officer of Bioretec</title>
<link>https://6ix.com/company/bioretec-ltd/news/tuukka-paavola-appointed-as-chief-financial-officer-of-bioretec-1</link>
<guid isPermaLink="true">https://6ix.com/company/bioretec-ltd/news/tuukka-paavola-appointed-as-chief-financial-officer-of-bioretec-1</guid>
<pubDate>Thu, 15 Jan 2026 15:59:00 GMT</pubDate>
<description>Bioretec Ltd., a pioneer in absorbable orthopedic implants appoints Tuukka Paavola (M.Sc. Industrial Engineering, CFA) as Chief Financial Officer, effective 20 January 2025. In this role, Paavola will report to Chief Executive Officer Sarah van Hellenberg Hubar-Fisher and will join the company's management team.</description>
</item>
<item>
<title>Bioretec Ltd's schedule for financial reporting and Annual General Meeting in 2026</title>
<link>https://6ix.com/company/bioretec-ltd/news/bioretec-ltds-schedule-for-financial-reporting-and-annual-general-meeting-in-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/bioretec-ltd/news/bioretec-ltds-schedule-for-financial-reporting-and-annual-general-meeting-in-2026-1</guid>
<pubDate>Mon, 22 Dec 2025 16:41:00 GMT</pubDate>
<description>In 2025, Bioretec will publish the following financial reports:</description>
</item>
<item>
<title>Inside information: Bioretec updates its strategy for 2026-2028 and provides new financial targets</title>
<link>https://6ix.com/company/bioretec-ltd/news/inside-information-bioretec-updates-its-strategy-for-2026-2028-and-provides-new-financial-targets-1</link>
<guid isPermaLink="true">https://6ix.com/company/bioretec-ltd/news/inside-information-bioretec-updates-its-strategy-for-2026-2028-and-provides-new-financial-targets-1</guid>
<pubDate>Tue, 16 Dec 2025 07:00:00 GMT</pubDate>
<description>As announced in September, Bioretec Ltd ("Bioretec" or the "Company") has assessed its overall commercialization strategy, pipeline, and options to accelerate growth. Bioretec's Board of Directors has today approved the Company's updated strategy for 2026–2028 and new financial targets for the strategy period.</description>
</item>
<item>
<title>Inside information: Bioretec has been granted FDA Breakthrough Device Designation status for its RemeOs™ DrillPin</title>
<link>https://6ix.com/company/bioretec-ltd/news/inside-information-bioretec-has-been-granted-fda-breakthrough-device-designation-status-for-its-remeostm-drillpin-1</link>
<guid isPermaLink="true">https://6ix.com/company/bioretec-ltd/news/inside-information-bioretec-has-been-granted-fda-breakthrough-device-designation-status-for-its-remeostm-drillpin-1</guid>
<pubDate>Sun, 14 Dec 2025 15:59:00 GMT</pubDate>
<description>Bioretec Oy ("Bioretec" or the "Company"), a pioneer in biodegradable orthopedic implants, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for its magnesium alloy technology-based, biodegradable RemeOs™ DrillPin.</description>
</item>
<item>
<title>Change negotiations completed at Bioretec</title>
<link>https://6ix.com/company/bioretec-ltd/news/change-negotiations-completed-at-bioretec-1</link>
<guid isPermaLink="true">https://6ix.com/company/bioretec-ltd/news/change-negotiations-completed-at-bioretec-1</guid>
<pubDate>Thu, 04 Dec 2025 10:47:00 GMT</pubDate>
<description>On November 12, 2025, Bioretec announced the start of statutory change negotiations under the Finnish Act on Co-operation within Undertakings, concerning the company's production and marketing operations in Finland. The aim of the negotiations was to streamline and reorganize operations in order to improve the company's competitiveness and profitability.</description>
</item>
</channel>
</rss>